IB Net Payout Yields Model

Invest like me - only at Covestor.com

Ouster: Priced For Death

By -

 

  • Ouster trades below $1 despite a building contract revenue opportunity and growing customer base.
  • The company just released new Lidar sensors based on an advanced digital chip improving detection range, precision and accuracy.
  • The stock trades at cash value despite a rapidly growing revenue base and being valued at 1.5x '23 sales targets.

A lot of SPAC deals were disasters, but some companies were just irrationally thrown away due to the stock market not understanding the business. Ouster (NYSE:OUST) continues to build a large order book as the company moves closer and closer to scale Lidar sensor production. My investment thesis remains ultra Bullish on the stock with the company releasing new sensors and cutting costs to eliminate share dilution going forward.
Read the full article on Seeking Alpha. 
Disclosure: No position mentioned. Please review the disclaimer page for more details. 
Update - Nov. 11
Ouster shook off the odd reaction following solid Q3 numbers and the Velodyne Lidar (VLDR) deal. The combined company has over $1 billion in backlog and the upside remains enormous in non-automotive Lidar. A move above the recent highs next week is likely and very bullish. 
Finviz Chart
Update - Nov. 7
As Ouster reported Q3'22 results, the company announced a merger with Velodyne Lidar. The companies are making a merger of equals to consolidate power in the non-automotive Lidar segment and implement massive costs savings in the process. 
  • Velodyne (NASDAQ:VLDR) shares gained 5% Monday morning after the lidar solutions firm agreed to merge with fellow lidar tech firm Ouster (NYSE:OUST) in an all-stock deal.
  • Under the terms of the deal, each Velodyne (VLDR) share will be exchanged for 0.8204 shares of Ouster (OUST) at closing. The transaction will result in existing Velodyne and Ouster shareholders each owning approximately 50% of the combined company, based on current shares outstanding.
  • The combined company is expected to drive lidar adoption and result in a strong financial position, increased operational efficiencies, ​​and a complementary customer base in fast-growing end-markets. The companies had a combined cash balance of ~$355M at Sep-end, and aim to realize annualized cost savings of at least $75M within nine months after deal closing.


Comments

Post a Comment

Popular posts from this blog

Occidental: Still Producing Too Much Oil

By -
Image
Though oil continues plunging, the oil giants continue producing more. For Q4, Occidental Petroleum (OXY) had roughly flat production. The worst part is that OXY plans to grow production by 2% to 4% in 2016. The stock has held up somewhat strong, but the inability to turn off the spigot remains troubling. Disclosure: No positions mentioned. Please review the disclaimer page for more details. 
Read more

ChargePoint: Low Quality Beat

By -
Image
  ChargePoint beat FQ2'22 revenue estimates, but the losses are mounting. The company guided up FY22 numbers partly due to acquisitions. The stock still trades at an estimated 21x FY23 number leaving limited upside for the stock and reinforcing why venture funds sold 13.8 million shares. Looking for a portfolio of ideas like this one? Members of Out Fox The Street get exclusive access to our model portfolio.  Learn More » After  solid FQ2'22 earnings ,  ChargePoint Holdings  ( CHPT ) has seen a nice bump in the stock. Now investors have to confront the valuation divide and deal with the past insider sales likely leading to future sales on any stock rallies. My  investment thesis  remains very Bearish on the EV charging station stock on any rallies into the mid-$20s. Read the full article on Seeking Alpha.  Disclosure: No position mentioned. Please review the disclaimer page for more details.  Update - Sept. 8 Be cautious when analysts strugg...
Read more

Aurora Cannabis: Deal Or No Deal

By -
Aurora Cannabis was left out of the major deal making in 2018. The cannabis company updated FQ2 guidance to revenues of $50 to $55 million with a continued focus on pure production growth. The stock is down as the market is becoming less impressed with commodity farming operations due to the prime Oregon example. The stock is below key resistance at $5.40 as medical cannabis patient totals failed to impress. As the end of 2018 came and went,   Aurora Cannabis   ( ACB ) was a notable absentee from the deal making in the cannabis market. Just about all of the other major Canadian cannabis players got large investments or signed up powerful partnerships, but the related stocks didn't generally maintain rallies following the deals. Based on the early legalization data in Canada and Oregon, the best option for Aurora Cannabis might actually be selling production capacity while the Canadian market remains hot. Read the full article on Seeking Alpha.  Disc...
Read more